In COVID-19 clinical update #68, Daniel Griffin discusses children acquiring infection at birthday parties, immunogenicity of vaccines in solid organ transplant patients, reinfection rates in recovered patients, lack of efficacy of azithromycin, bacterial and fungal infections in hospitalized patients, effect of monoclonal antibody treatment on clinical outcomes of ambulatory patients, and reduction in mortality of hospitalized patients treated with remedesivir.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 772 (23 MB .mp3, 38 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- COVID-19 and birthday parties (JAMA) 6:46
- Vaccines in transplant patients (Ann Int Med) 9:22
- Reinfection of recovered patients (Clin Inf Dis) 13:00
- Azithromycin lack of efficacy (Rev Med Virol) 15:27
- Bacterial and fungal infections in hospitalized patients (Op For Inf Dis) 17:16
- mAb treatment of ambulatory patients (Op For Inf Dis) 19:21
- Remdesivir reduction of mortality (Gilead) 20:26
- Letters read on TWiV 772 31:10
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
I think the mAb treatment link should be Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19.